Featured

The target is a biotechnology company focused on next-generation antibody therapies for severe and life-threatening diseases, particularly cancer.

The target is a diversified medical technology company with several specialties.

The transaction is expected to provide a minimum of $66 million in net proceeds after transaction expenses.

Stardust Power’s strategy is to become a leading domestic producer of battery grade lithium products.

If approved, the proceeds are expected to fully fund the construction of the first phase of Sio’s extraction and processing facility in Winnipeg, Manitoba.

The transaction is expected to provide the combined company with approximately $87 million of gross proceeds (assuming no further redemptions from Concord’s trust).

Aetherium will ascribe to Capital A International an indicative equity value of $1 billion alongside additional net cash proceeds.

In addition to the $400 million in stock, 20 million shares of Feutune Light are to be set aside in escrow as earnout shares at closing.

The target develops cancer therapies. Upon closing Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%.

The target is an Argentina-based, low-cost airline.